Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from ...

Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Stryker is in advanced discussions to acquire Inari Medical, a company producing devices for venous diseases. If successful, the acquisition, valued at nearly $3 billion, would enhance Stryker's ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Stryker plans to acquire Inari Medical for $4.9 billion to enhance its venous disease treatment portfolio. Inari, valued at nearly $3 billion, has seen increased interest amid growth in medical device ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Inari Medical (NARI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Sarcone ...